ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Shares Acquired by Geode Capital Management LLC

Geode Capital Management LLC boosted its holdings in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) by 4.2% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 425,225 shares of the specialty pharmaceutical company’s stock after buying an additional 17,314 shares during the quarter. Geode Capital Management LLC owned approximately 2.02% of ANI Pharmaceuticals worth $25,373,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently bought and sold shares of ANIP. Barclays PLC raised its position in shares of ANI Pharmaceuticals by 1,681.2% during the 3rd quarter. Barclays PLC now owns 143,033 shares of the specialty pharmaceutical company’s stock worth $8,534,000 after acquiring an additional 135,003 shares in the last quarter. Y Intercept Hong Kong Ltd purchased a new stake in shares of ANI Pharmaceuticals during the 3rd quarter worth approximately $405,000. State Street Corp boosted its holdings in shares of ANI Pharmaceuticals by 9.1% in the 3rd quarter. State Street Corp now owns 703,843 shares of the specialty pharmaceutical company’s stock valued at $41,991,000 after buying an additional 58,698 shares in the last quarter. Stifel Financial Corp purchased a new position in shares of ANI Pharmaceuticals in the 3rd quarter valued at $418,000. Finally, Janus Henderson Group PLC raised its stake in ANI Pharmaceuticals by 83.7% during the 3rd quarter. Janus Henderson Group PLC now owns 9,510 shares of the specialty pharmaceutical company’s stock worth $568,000 after acquiring an additional 4,333 shares in the last quarter. 76.05% of the stock is currently owned by institutional investors and hedge funds.

ANI Pharmaceuticals Price Performance

ANI Pharmaceuticals stock opened at $54.41 on Friday. The company has a debt-to-equity ratio of 1.52, a current ratio of 2.74 and a quick ratio of 1.97. The business has a 50 day simple moving average of $57.48 and a 200-day simple moving average of $59.68. ANI Pharmaceuticals, Inc. has a 12 month low of $52.50 and a 12 month high of $70.81. The stock has a market capitalization of $1.14 billion, a PE ratio of -98.93 and a beta of 0.73.

ANI Pharmaceuticals (NASDAQ:ANIP) last announced its quarterly earnings data on Friday, November 8th. The specialty pharmaceutical company reported $1.34 EPS for the quarter, topping analysts’ consensus estimates of $1.09 by $0.25. The company had revenue of $148.30 million during the quarter, compared to the consensus estimate of $144.37 million. ANI Pharmaceuticals had a negative net margin of 1.28% and a positive return on equity of 15.87%. ANI Pharmaceuticals’s quarterly revenue was up 12.5% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.05 EPS. Equities analysts predict that ANI Pharmaceuticals, Inc. will post 3.87 earnings per share for the current year.

Insider Activity at ANI Pharmaceuticals

In related news, CEO Nikhil Lalwani sold 33,481 shares of ANI Pharmaceuticals stock in a transaction that occurred on Tuesday, November 26th. The stock was sold at an average price of $57.99, for a total value of $1,941,563.19. Following the sale, the chief executive officer now directly owns 370,378 shares in the company, valued at $21,478,220.22. The trade was a 8.29 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, SVP Krista Davis sold 1,000 shares of the stock in a transaction on Wednesday, December 11th. The stock was sold at an average price of $60.00, for a total value of $60,000.00. Following the completion of the transaction, the senior vice president now owns 49,059 shares of the company’s stock, valued at $2,943,540. The trade was a 2.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 42,231 shares of company stock worth $2,434,286 over the last 90 days. Company insiders own 12.70% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have issued reports on ANIP shares. Leerink Partnrs raised ANI Pharmaceuticals to a “strong-buy” rating in a report on Wednesday, December 11th. Leerink Partners began coverage on ANI Pharmaceuticals in a research note on Wednesday, December 11th. They set an “outperform” rating and a $80.00 price target on the stock. Truist Financial boosted their price objective on ANI Pharmaceuticals from $60.00 to $62.00 and gave the company a “hold” rating in a research note on Tuesday, October 22nd. Raymond James raised their target price on shares of ANI Pharmaceuticals from $81.00 to $83.00 and gave the stock an “outperform” rating in a research report on Wednesday, September 18th. Finally, Piper Sandler initiated coverage on shares of ANI Pharmaceuticals in a research report on Friday, October 11th. They issued an “overweight” rating and a $68.00 price target for the company. Two analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $77.71.

ANI Pharmaceuticals Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.